Trial Profile
A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary) ; Ranolazine (Primary)
- Indications Diastolic heart failure
- Focus Therapeutic Use
- Acronyms RALI-DHF
- 14 Apr 2012 New source identified and integrated (European Clinical Trials Database EudraCT2009-017168-17).
- 27 Mar 2012 Results presented at the 61st Annual Scientific Session of the American College of Cardiology.
- 18 Mar 2011 Planned end date changed from 1 Jan 2012 to 1 Feb 2011 as reported by ClinicalTrials.gov.